Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ropivacaine + radiopaque contrast is a combination used primarily in interventional pain management and regional anesthesia procedures, particularly for continuous epidural infusion. Ropivacaine is an amide-type local anesthetic that works by blocking sodium channels on nerve fibers, thereby inhibiting the initiation and conduction of nerve impulses to provide regional or local anesthesia and acute pain relief. The addition of a radiopaque contrast agent (commonly iohexol or other iodinated compounds) allows real-time imaging (e.g., under CT or fluoroscopy) to visualize the spread of the anesthetic solution within the epidural space, ensuring accurate placement and distribution. This combination is not a commercial product but rather a procedural mixture prepared for specific clinical indications where both analgesia and imaging guidance are required[1][8]. The primary indication is for procedures requiring both effective pain control and confirmation of drug spread via imaging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ropivacaine + radiopaque contrast.